BrightGene Bio Medical Technology C (688166) — Cash Flow-to-Debt Ratio
BrightGene Bio Medical Technology C (688166) has a Cash Flow-to-Debt Ratio of 0.01x as of June 2023, meaning its operating cash flow of CN¥26.70 Million could theoretically repay 0% of its total liabilities (CN¥2.46 Billion) in one year. See BrightGene Bio Medical Technology C (688166) flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BrightGene Bio Medical Technology C Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for BrightGene Bio Medical Technology C across 9 annual periods. For the full cash flow conversion analysis, see BrightGene Bio Medical Technology C (688166) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year debt coverage analysis for BrightGene Bio Medical Technology C. Check earnings quality score of BrightGene Bio Medical Technology C to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.09x | CN¥245.56 Million | CN¥2.73 Billion | ▲ +20.9% |
| 2023 | 0.07x | CN¥194.77 Million | CN¥2.61 Billion | ▼ -42.1% |
| 2022 | 0.13x | CN¥311.26 Million | CN¥2.42 Billion | ▼ -10.3% |
| 2021 | 0.14x | CN¥176.08 Million | CN¥1.23 Billion | ▼ -63.5% |
| 2020 | 0.39x | CN¥155.43 Million | CN¥395.23 Million | ▼ -30.6% |
| 2019 | 0.57x | CN¥61.33 Million | CN¥108.21 Million | ▼ -6.5% |
| 2018 | 0.61x | CN¥63.99 Million | CN¥105.52 Million | ▲ +33.8% |
| 2017 | 0.45x | CN¥35.77 Million | CN¥78.89 Million | ▲ +150.1% |
| 2016 | 0.18x | CN¥29.73 Million | CN¥164.05 Million | — |